Vertex Pharmaceuticals, Inc. (VRTX) Posts Q1 Loss of 65c/Share; Reports Statistically Significant KALYDECO + VX-661 Ph. 2 Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Vertex Pharmaceuticals, Inc. (VRTX) Posts Q1 Loss of 65c/Share; Reports Statistically Significant KALYDECO + VX-661 Ph. 2 Data

Goldman Sachs Comments on Vertex (VRTX)

May 2, 2014 9:39 AM EDT

Goldman Sachs maintained a Neutral rating on Vertex (NASDAQ: VRTX) with a price target of $64.00.

Analyst Terence Flynn said, "In our view 1Q results were uneventful and the focus remains on... More

Vertex (VRTX): H.C. Wainwright Comments on VX-661 Data

May 2, 2014 9:33 AM EDT

H.C. Wainwright maintained a Buy rating on Vertex (NASDAQ: VRTX) with a price target of $105.00. Comments follow data on VX-661.

Analyst Andrew S. Fein said, "Yesterday, VRTX took the final step in its transformation into a CF company by simultaneously eliminating the vestigial VX-135 and by reporting additional positive clinical data on VX-661, which over the course of the last 12... More

Vertex (VRTX) Bullish Stance Reiterated at Needham & Company after Q1 Results, Encouraging VX-661-Ivacaftor Phase 2 Data

May 2, 2014 7:41 AM EDT

Needham & Company analyst Alan Carr reiterated a Buy rating and $95 price target on Vertex (NASDAQ: VRTX) following Q1 results and 'encouraging' VX-661-ivacaftor phase 2 data.

Carr commented, "Vertex reported 1Q14 financial results yesterday and announced positive top-line results from a Phase 2... More